Completed PHASE2 INTERVENTIONAL 2-arm NCT02111122

Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease (PD-Xyrem)

A Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

Sponsor: Christian Baumann

Conditions Sleep-wake Disturbances in Motor-phase Parkinson's Disease

Interventions Placebo Sodium Oxybate

Updated 7 times since 2017 Last updated: Jan 21, 2021 Started: Apr 30, 2014 Primary completion: Apr 30, 2016 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Sleep-wake Disturbances in Motor-phase Parkinson's Disease, this trial is completed. The trial is conducted by Christian Baumann and has accumulated 7 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Sep 2020 — Dec 2020 [monthly]

Unknown Status PHASE2
Jan 2017 — Sep 2020 [monthly]

Unknown Status PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Christian Baumann

Data source: University of Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland